Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2009

01-12-2009 | Letter to the Editor

Stroke due to doxorubicin-induced cardiac toxicity

Authors: Gamze Kara, Özlem Taşoğlu, Ömer Dizdar, Kadri Altundağ, Levent Özçakar

Published in: Medical Oncology | Issue 4/2009

Login to get access

Excerpt

To the editor, …
Literature
1.
2.
3.
You RX, et al. Risk factors for stroke due to cerebral infarction in young adults. Stroke. 1997;28:1913–8.PubMed
4.
5.
Dietrich J, Marienhagen J, Schalke B, Bogdahn U, Schlachetzki F. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother. 2004;38:242–6. doi:10.​1345/​aph.​1D106.PubMed
6.
7.
Metadata
Title
Stroke due to doxorubicin-induced cardiac toxicity
Authors
Gamze Kara
Özlem Taşoğlu
Ömer Dizdar
Kadri Altundağ
Levent Özçakar
Publication date
01-12-2009
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 4/2009
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-008-9134-3

Other articles of this Issue 4/2009

Medical Oncology 4/2009 Go to the issue

Original Paper

Patient rationale in selecting androgen deprivation (PRISAD): do we give patients what they want?

Original Paper

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor

Original Paper

Ifosfamide-based chemotherapy in locoregionally advanced nasopharyngeal cancer: evaluation of its role as neoadjuvant chemotherapy

Case Report

A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection

Letter to the Editor

Matrilysin: a rapidly expanding role in the etiopathogenesis of systemic malignancies

Original Paper

Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits